Transfusion and Apheresis Science最新文献

{"title":"Colleagues from around the world have given generously of their time and expertise to produce The 2024 International Survey of Platelet Products and Practice and two related manuscripts in this issue of Transfusion and Apheresis Science","authors":"Kenneth E. Nollet, Hitoshi Ohto","doi":"10.1016/j.transci.2025.104085","DOIUrl":"10.1016/j.transci.2025.104085","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104085"},"PeriodicalIF":1.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143348949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adapting the Cohn 6th cold ethanol fractionation method for small plasma pools: An innovative platform for developing hyperimmunoglobulin products against antibiotic-resistant infections in resource-limited settings","authors":"Mikayel Ginovyan ,&nbsp;Gayane Kirakosyan","doi":"10.1016/j.transci.2025.104093","DOIUrl":"10.1016/j.transci.2025.104093","url":null,"abstract":"<div><div>The growing challenge of antimicrobial resistance (AMR) requires innovative strategies to combat multidrug-resistant infections. Vaccination is an effective approach, often considered a potential solution, however, its application against some of the most challenging multidrug-resistant bacteria, has been unsuccessful so far. In contrast, passive immunotherapy using high-titer specific antibodies can offer immediate solutions for infections where conventional antibiotics fail. This study describes the adaptation of the Cohn 6th cold ethanol fractionation method for small plasma pools, enabling the production of high-quality intravenous immunoglobulin (IVIG) products in resource-limited settings. Using small-scale plasma batches (12 L), the modified protocol achieved a yield of 4.5 ± 0.2 g/L IgG with &gt; 98 % purity, meeting European Pharmacopoeia requirements. Additional purification, viral safety, and filtration steps ensured sterility, low endotoxin levels, and robust viral inactivation. Safety evaluations confirmed sterility, absence of pyrogens, and stability over 24 months. This scalable methodology provides a practical platform for developing hyperimmunoglobulin products targeting AMR pathogens, particularly in resource-limited countries where large-scale fractionation infrastructure is unavailable and also not suitable. Our future efforts will focus on integrating this platform into combination therapies to enhance clinical outcomes in AMR infection management.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104093"},"PeriodicalIF":1.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143286781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial commentary","authors":"Jerard Seghatchian","doi":"10.1016/j.transci.2025.104089","DOIUrl":"10.1016/j.transci.2025.104089","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104089"},"PeriodicalIF":1.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAPRIN2 RNA-binding protein contributes to balance erythroid production: Implications in the fine-tuning of proteostasis during erythropoiesis","authors":"Zacaria Jaiteh ,&nbsp;Reinier van der Linden ,&nbsp;John Kong-A-San ,&nbsp;Alex Maas ,&nbsp;Sjaak Philipsen ,&nbsp;Frank Grosveld ,&nbsp;Laura Gutiérrez","doi":"10.1016/j.transci.2025.104092","DOIUrl":"10.1016/j.transci.2025.104092","url":null,"abstract":"<div><div>Erythropoiesis is a process that requires tight control of gene transcription, mRNA stability, and protein synthesis and degradation. These regulatory layers adapt dynamically to developmental needs and physiological stresses, ensuring precise control of erythroid production. Ribosomopathies, such as Diamond-Blackfan anemia (DBA), are characterized by defects in ribosome function. Zooming in on erythroid precursors, ribosomopathies lead to dysregulated translation of mRNAs encoding specific and essential erythropoietic genes, including master transcription factors such as GATA1. This causes defective maturation and increased apoptosis of erythroid progenitors, and consequently, anemia. Beyond ribosomal proteins, RNA-binding proteins have been put forward as an additional and targeted checkpoint regulating cellular proteostasis. CAPRIN2, which is present in neurons and erythroid cells, is one such RNA-binding protein, involved in RNA translation regulation and its levels rise during terminal erythroid differentiation. Overexpression of CAPRIN2 in Chinese hamster ovary (CHO) cells causes reduced growth, cell cycle arrest, and apoptosis. Here, we demonstrate that GATA1 potentially regulates <em>Caprin2</em> transcription, and that <em>Caprin2</em> loss boosts erythroid production and maturation during gestation and adulthood, a phenomenon that is enhanced in situations of stress erythropoiesis. Our results provide new insight into the role of CAPRIN2 in erythropoiesis. We hypothesize that it regulates the translation of key mRNAs during erythropoiesis. We propose that CAPRIN2 is involved in the balance of erythroid production and that its manipulation may control erythroid production, offering a potential and promising approach to manage altered erythropoiesis.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104092"},"PeriodicalIF":1.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143348950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on the measurement of \"soluble angiotensin converting enzyme 2\" in plasma and its emerging significance as a novel biomarker of cardiovascular and kidney diseases: A concise commentary","authors":"Jean Amiral,&nbsp;Rémy Ferol","doi":"10.1016/j.transci.2025.104090","DOIUrl":"10.1016/j.transci.2025.104090","url":null,"abstract":"<div><div>Angiotensin Converting Enzyme 2 has emerged as a major cell-surface enzyme receptor for controlling the Renin-Angiotensin-Aldosterone-System. The SARS-Cov-2 pandemics has focused a major interest on that cell-surface receptor. It is the virus entry door for cell infection, and when inside it can replicate and lead to cell destruction. In some physio-pathological conditions, ADAM 17 and TMPSSR2 enzymes can cleave ACE2 on the cell surface and release its extra-cellular domain into the blood circulation. Measurement of this soluble protein then becomes possible, preferentially in plasma, but also in serum. Clinical studies have shown that Soluble ACE2 is an emerging biomarker for cardiovascular and kidney diseases and it could be of prognostic value for heart failure and kidney dysfunctions. In Covid-19 its diagnostic value is controversial, and the various studies lead to different conclusions. Many laboratory assays have been reported for the measurement of this biomarker. They concern enzymatic assays, aptamer methods, or immunoassays, either chemiluminescent or ELISA. Normal and pathological plasma concentrations reported with the various assays yet lack standardization and are very heterogenous. Recently introduced immunoassays tend to yield more compliant results despite variations due to the assay design and calibration, or the antibody targeted epitopes and reactivity. This article reports an ELISA designed with affinity purified rabbit polyclonal antibodies, obtained with recombinant ACE2 and calibrated with the recombinant protein in plasma. This assay has a global reactivity with the various ACE2 protein epitopes. Assay performance characteristics, and values measured in normal populations are presented. Availability of optimized ELISAs can contribute to a better harmonization of sACE2 measurements in plasma, and confirm its clinical significance as biomarker.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104090"},"PeriodicalIF":1.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative assessment of hemostasis in septic patients and healthy controls using standard coagulation tests and whole-blood thromboelastometry","authors":"Ecaterina Scarlatescu ,&nbsp;Paul Y. Kim ,&nbsp;Sergey P. Marchenko ,&nbsp;Dana R. Tomescu","doi":"10.1016/j.transci.2025.104082","DOIUrl":"10.1016/j.transci.2025.104082","url":null,"abstract":"<div><h3>Background</h3><div>Sepsis is associated with dysregulation of procoagulant, anticoagulant, and fibrinolytic pathways.</div></div><div><h3>Aims</h3><div>To compare the measurements of coagulation activation, clot formation, stabilization, and lysis between rotational thromboelastometry (ROTEM) and standard coagulation tests (SCTs) on patients with early sepsis (SP) and healthy controls (HC).</div></div><div><h3>Methods</h3><div>This observational study included 30 SP and 30 HC. At study inclusion, SCTs and ROTEM analyses were conducted. A modified ROTEM with exogenous tPA was used to investigate fibrinolysis resistance.</div></div><div><h3>Results</h3><div>SP had longer prothrombin time, higher fibrinogen levels and lower platelet count compared to HC. On ROTEM, clotting initiation was longer in SP than in HC but median clotting time maintained within reference ranges. SP had higher maximum velocity of clot formation, clot firmness, elasticity, and platelet component than HC. Clot lysis indices (CLI) were higher in EXTEM and APTEM (without and with added tPA) in SP compared to HC. The difference in CLI between APTEM and EXTEM was lower for both native and tPA-spiked samples in SP compared with HC.</div></div><div><h3>Conclusions</h3><div>While SCTs suggest SP are hypocoagulable, VET revealed normal coagulation initiation in more than 80 % of SP. Compared to HC, SP had increased clot propagation, firmness and elasticity, and decreased platelet-mediated clot retraction and lysis. In sepsis, VET provide more comprehensive information about hemostatic changes than SCTs.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104082"},"PeriodicalIF":1.4,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143148931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?","authors":"Turgay Ulas ,&nbsp;Sinem Namdaroglu ,&nbsp;Ipek Yonal Hindilerden ,&nbsp;Mehmet Ali Erkurt ,&nbsp;Kerim Erer ,&nbsp;Tugce Nur Yigenoglu ,&nbsp;Tarik Onur Tiryaki ,&nbsp;Emine Hidayet ,&nbsp;Serdal Korkmaz ,&nbsp;Bahar Uncu Ulu ,&nbsp;Seda Yilmaz ,&nbsp;Emin Kaya ,&nbsp;Mehmet Sezgin Pepeler ,&nbsp;Abdulkadir Basturk ,&nbsp;Mehmet Sinan Dal ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2024.104058","DOIUrl":"10.1016/j.transci.2024.104058","url":null,"abstract":"<div><h3>Objectives</h3><div>In this study, we aimed to compare the engraftment days, graft versus host disease (GVHD) development, relapse and overall survival (OS) rates in patients using variable intensity conditioning regimens with two different post-transplant cyclophosphamide (PTCy) doses for hematological malignancies.</div></div><div><h3>Material and methods</h3><div>We retrospectively analyzed 162 patients who have had PTCy at a dose of 25 mg/kg × 2 and 50 mg/kg × 2 between 2018 and 2024. Patients were divided in 2 groups; PTCy dose with 25 mg/kg × 2 (Group 1, n = 45) and PTCy dose with 50 mg/kg × 2 (Group 2, n = 117). The engraftment days, GVHD, relapse and OS rates were compared across groups.</div></div><div><h3>Results</h3><div>All patients had myeloablative conditioning regimens and peripheral stem cell collected transplantation. 61.1 % of patients (n = 99) were alive at the end of the study (60 % (n = 27) in Group1 and 61.5 % (n = 72) in Group 2). In Group 1 the median follow-up was 6.9 months and in Group 2 this was 7 months; the median OS was 15.5 months in Group 1 and 49.5 months in Group 2 but this is not statistically significant (Log rank = 0.796). In Group 1, the engraftment times for platelets was 13 days, for neutrophils 17 days; in Group 2, for platelet this was 18 days; and for neutrophils 17 days; this was statistically significant for platelets but not for neutrophil engraftment (p: &lt; 0.001 and p:0.839, respectively). Eighteen patients (40 %) in Group 1 and twenty-seven (23 %) patients in group 2 had acute GVHD (aGVHD). In Group 1 aGVHD rates were higher than Group 2 (p = 0.031). Seven patients (15.5 %) in Group 1 and 6 (5.12 %) patients in group 2 had chronic GVHD (cGVHD). In Group 1 cGVHD rates were also higher than Group 2 (p = 0.048). Twenty-five patients (55.6 %) in Group 1 and 19 patients (16.2 %) in Group 2 had relapsed disease (p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Our study showed that there were no differences in survival across the groups. The platelet engraftment time was shorter for the PTCy 25 mg/kg × 2 doses compared to the post-transplantation 50 mg/kg × 2 doses. Both aGVHD and cGVHD rates were higher in 25 mg/kg × 2 dose treated patients. Relapses occurred more commonly with 25 mg/kg × 2 PTCy dose.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104058"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in patients with thrombotic microangiopathy associated with a trigger following plasma exchange: A systematic literature review","authors":"Shinya Kaname ,&nbsp;Moh-Lim Ong ,&nbsp;Jonathan Mathias ,&nbsp;Francesca Gatta ,&nbsp;Lisa Law ,&nbsp;Yan Wang","doi":"10.1016/j.transci.2024.104048","DOIUrl":"10.1016/j.transci.2024.104048","url":null,"abstract":"<div><div>Plasma exchange (PE) outcomes in patients with trigger-associated thrombotic microangiopathy (TMA) have not been comprehensively reviewed. Embase and MEDLINE® were searched on 03/14/2022 for English language articles published after 2007, alongside a congress materials search (2019–2022; PROSPERO: CRD42022325170). Studies with patients with trigger-associated TMA (excluding thrombotic thrombocytopenic purpura, ‘typical’ hemolytic uremic syndrome caused by Shiga toxin-producing <em>Escherichia coli</em>, post-partum TMA, and TMAs with known genetic cause) who received PE or plasma infusion (PI) and reported treatment response (including measures), safety, patient-/caregiver-reported outcomes, or economic burden data were examined. The NICE quality appraisal checklist assessed bias risk. After screening 695 articles, 49 PE or PI studies were identified, of which 42 reported PE exclusively; most were retrospective observational studies (n = 37). The most common TMA trigger was transplantation (n = 12). The median number of PE sessions was 3.5–25.0. Outcomes following PE varied by trigger type. Treatment response rates and definitions varied (0–100 %; 24 studies); in studies of &gt; 25 patients, response rates were 5–63 %. TMA relapse rates were 0–67 % (7 studies). Mortality was 10–91 % (23 studies). Progression to chronic kidney disease (CKD; 5 studies) and end-stage renal disease (ESRD; 6 studies) occurred in 0–93 % and 17–100 % of patients, respectively. Two serious adverse events were identified (transfusion-related injury, acute lung injury; 10 studies; 231 patients). Patients with trigger-associated TMA may experience a substantial burden in terms of mortality, relapse, and progression to CKD and ESRD following PE, leading to increased healthcare resource utilization. Additional interventions may be required.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104048"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of anticoagulant combinations used in granulocyte apheresis","authors":"Bera Omer Ugurlu ,&nbsp;Tulay Karaagac Akyol ,&nbsp;Olgu Erkin Çınar ,&nbsp;Osman Ozcebe","doi":"10.1016/j.transci.2024.104044","DOIUrl":"10.1016/j.transci.2024.104044","url":null,"abstract":"<div><div>Our study retrospectively examines the number of granulocytes in the products of donors who donated granulocytes between January 2016 and September 2020 at the Hacettepe University Faculty of Medicine Blood Bank. The effects of acid-citrate-dextrose (ACD), trisodium citrate + hydroxyethyl starch (TCC + HES) and ACD + HES combinations used in the apheresis procedure on the granulocyte count of apheresis products were examined. As a result of study, it was seen that the type of anticoagulant combination used during apheresis significantly affected the number of granulocytes collected.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104044"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?","authors":"Tugce Nur Yigenoglu ,&nbsp;Mehmet Ali Erkurt ,&nbsp;Simten Dagdas ,&nbsp;Bahar Uncu Ulu ,&nbsp;Irfan Kuku ,&nbsp;Ali Durdu ,&nbsp;Mehmet Sezgin Pepeler ,&nbsp;Sinem Kul ,&nbsp;Mehmet Sinan Dal ,&nbsp;Emin Kaya ,&nbsp;Serdal Korkmaz ,&nbsp;Turgay Ulaş ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2024.104057","DOIUrl":"10.1016/j.transci.2024.104057","url":null,"abstract":"<div><h3>Objective</h3><div>Acute graft versus host disease (GVHD) occurs in 20–80 % of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Of these patients, 40 % will be resistant to steroids, which is the standard first-line approach. There is no standard second line treatment approach for patients with steroid refractory acute GVHD (SR-aGVHD). Alpha-1 antitrypsin is a protease inhibitor and has anti-inflammatory and immune regulatory properties. Here we report the outcomes and safety data of 17 patients treated with alpha-1 antitrypsin for SR-aGVHD.</div></div><div><h3>Material and methods</h3><div>Patients who received at least 2 lines of alpha-1 antitrypsin treatment for SR-aGVHD at five transplant centers in Türkiye were included in this retrospective study.</div></div><div><h3>Results</h3><div>The median number of alpha-1 antitrypsin treatment line patients received was 4 (range, 2–5). The median time between alpha-1 antitrypsin administration and response was 65 days (range, 10–138 days). Overall response rate was 70.6 %. When the first- and second-month response rates were compared according to GVHD organ involvement, we found that the response rates were similar in skin, liver and gastrointestinal system involvement (p = 0.281 and p = 0.305, respectively). No grade 3–4 anemia, thrombocytopenia or neutropenia was observed after alpha-1 antitrypsin treatment. Two patients had cytomegalovirus infection and 1 patient had pneumonia. At a median follow-up of 7 months, overall survival was 70.6 % and median overall survival was not reached.</div></div><div><h3>Conclusion</h3><div>In conclusion, alpha-1 antitrypsin is an effective and safe treatment option in patients with SR-aGVHD, with response rates of up to 70 % in patients with skin, liver and gastrointestinal system involvement. Larger studies are needed to establish a standard second and subsequent treatment approach in patients with SR-aGVHD.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104057"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}